The complaint centers on the period between November 25, 2025, and May 4, 2026, during which management repeatedly characterized the company’s pen needle portfolio as resilient. Plaintiffs argue these assurances were materially false, as leadership allegedly ignored significant market softness and a major customer share loss. This disconnect between public guidance and internal performance became public on May 5, 2026.
Embecta Investors File Lawsuit Over Alleged Insulin Needle Misstatements
A 57.8% single-day stock plunge has triggered a federal securities class action against Embecta Corp. The lawsuit, filed in New Jersey, alleges the medical device company misled shareholders by painting a picture of stability for its insulin pen needle business while facing hidden competitive losses and retail volume declines.
Upon revealing its second-quarter fiscal 2026 financial results, Embecta disclosed a massive revenue shortfall. The company subsequently slashed its full-year 2026 adjusted earnings per share guidance by 43% and reduced its quarterly dividend by 93%, from $0.15 to $0.01 per share. Reed Kathrein, a partner at Hagens Berman, stated the firm is investigating whether those earlier claims were intentionally misleading given the later admission of market headwinds. Investors holding losses from this period have until August 17, 2026, to file as lead plaintiffs.
Comments (0)
No comments yet. Be the first!